Global Calcium is one of the leading manufacturers and exporters of
Indomethacin CAS no. 53-86-1, API, (Active Pharmaceutical Ingredient). We support the customers with exhaustive documentation. As a USDMF & EU-GMP certified global company and an established hallmark for pharmaceutical standards, Global Calcium has stood the test of time since its inception in 1979.
As manufacturer of Indomethacin we hereby state the following facts about the drug:
Indomethacin is NSAID with anti-inflammatory, analgesic, and antipyretic properties. It is a synthetic nonsteroidal indole derivative with anti-inflammatory activity and chemopreventive properties. Indomethacin inhibits the enzyme cyclooxygenase, thereby preventing cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines. This agent also may inhibit the expression of multidrug-resistant protein type 1, resulting in increased efficacies of some antineoplastic agents in treating multi-drug resistant tumors. In addition, indomethacin activates phosphatases that inhibit the migration and proliferation of cancer cells and downregulates survival, which may result in tumor cell apoptosis.
Oral indomethacin is indicated for symptomatic management of moderate to severe rheumatoid arthritis including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, and acute painful shoulder (bursitis and/or tendinitis), and acute gouty arthritis. Intravenous indomethacin is indicated to induce closure of a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours of usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective.
Indomethacin is a potent NSAID typically used for chronic inflammatory arthritis. Indomethacin has been associated with rare cases of idiosyncratic drug-induced liver disease.
Mechanism of action:
The anti-inflammatory, analgesic, and antipyretic effects of indomethacin and other NSAIDs, including selective inhibitors of cyclooxygenase-2 (COX-2) (e.g., celecoxib), appear to result from the inhibition of prostaglandin synthesis. While the precise mechanism of the anti-inflammatory and analgesic effects of NSAIDs continues to be investigated, these effects appear to be mediated principally through inhibition of the COX-2 isoenzyme at sites of inflammation with subsequent reduction in the synthesis of certain prostaglandins from their arachidonic acid precursors. This effect may be related to the inhibition of the synthesis of prostaglandins that are believed to play a role in modulating the rate and extent of leukocyte infiltration during inflammation. Indomethacin also inhibits lysosomal enzyme release from polymorphonuclear leukocytes.
Global Calcium is a leading manufacturer of this drug. We manufacture this pharmaceutical drug and make it available to domestic and overseas market